Effect of Rifampicin on the Pharmacokinetics of Lenvatinib in Healthy Adults

2014 
Background and Objectives Lenvatinib is an oral, multitargeted tyrosine kinase inhibitor under clinical investigation in solid tumours. This study evaluated the influence of P-glycoprotein (P-gp) inhibition (single-dose rifampicin) and simultaneous cytochrome P450 3A4 (CYP3A4)/P-gp induction (multiple-dose rifampicin) on lenvatinib pharmacokinetics.
    • Correction
    • Source
    • Cite
    • Save
    • Machine Reading By IdeaReader
    22
    References
    39
    Citations
    NaN
    KQI
    []